trending Market Intelligence /marketintelligence/en/news-insights/trending/b4EXqkjl6HOhdf-_98BdpA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aptevo Therapeutics secures $35M investment from Lincoln Park Capital Fund

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Aptevo Therapeutics secures $35M investment from Lincoln Park Capital Fund

Aptevo Therapeutics Inc. said Chicago-based asset manager Lincoln Park Capital Fund LLC has committed to buy $35 million of its common stock.

Aptevo Therapeutics plans to use the net proceeds from the share sale to further develop bispecific antibody candidates using its ADAPTIR platform. Bispecific antibodies are artificial proteins designed to simultaneously bind to two different types of antigen — a toxin or other foreign substance that induces the body's immune response.

Under the purchase agreement, Lincoln Park Capital Fund is obligated to buy shares, at Aptevo Therapeutics request, over a 36-month period. Aptevo Therapeutics has also issued shares to the asset manager as commitment shares and will issue additional commitment fee shares upon the effectiveness of the registration statement.

Aptevo Therapeutics can terminate the agreement at any time without any cost or penalty.

Aptevo Therapeutics is a biotechnology company that develops treatments for cancer and blood-related diseases.